Cancer is a genetic disease. Every human being is different and unique, so is his/her cancer. However, the conventional ‘standard of care’ approaches are based on population studies, which disregard the unique genetic landscape and complex metabolic dynamics of the tumor. As a result, the patients are at risk of failed therapies or aggressive relapse. It is, thus, imperative that the genetic architecture of the tumor is studied comprehensively before deciding the treatment plan, which has to be personalised to the individual patient and his/her disease.